Supplies and Logistics

Priority Essential Medicines for Child Survival, September 2010

A two day meeting on priority essential medicines for children, hosted by UNICEF Supply Division in collaboration with the World Health Organization (WHO), brought together experts in paediatric medicines from academia, the pharmaceutical industry (both innovator and generic), regulators, programme managers and implementers. The purpose of the meeting was to reach a consensus on what are priority essential medicines for children, and to identify the steps required to ensure that these medicines are available and affordable.

Outcome
Product specifications were described for each priority medicine, as both ‘base case’ and ‘best case’ scenarios, to enable the development of the optimal dosage forms of these medicines for children. Specifications should include information about optimal packaging and pack size, taking account of the conditions in countries with high child mortality where supply systems are fragile, storage conditions are often not ideal, and human resources for health are limited.

Health workers and caregivers require products that are easy to use, and children require medicines that address their special needs. Topics where more work and/or evidence are required before product specifications can be developed were also identified. The outcome of the meeting will be used as the basis for deliberations with the pharmaceutical industry, drug regulators, policy makers and implementers to make these priority essential medicines available and affordable.

Read the full report here

 

Presentations

Day 1

Qazi Shamin Ahmed, WHO - Child and Adolescent Health

Suzanne Hill, WHO - Essential Medicines and Policy (EMP)

Kelita Kamoto, MOH Malawi - Product Characteristics, Perspectives from Community Health Workers in Malawi

Carine Werder, MSF - Paediatric Medicines MSF field experiences

Tonny Nunn, MCRN/NIHR - Dosage form issues and gaps

Alexis Heaton, JSI - The Supply Chain Perspective

Marcel de Matas, Bradford University - Formulating Drug Products for Children

Tom Sam, IFPMA - R&D Pharmaceutical Industry Perspective on Specifications for Pediatric Medicines

Christine Strunz Lehner, Sandoz - Developing paediatric medication

Day 2

David Rupin, Clinton foundation - Challenges and Barriers to Access

Francisco Blanco, UNICEF - Sources and Prices of selected medicines for children

Penny Grewal Daumeri, MMV - Increasing the supply base of paediatric antimalarials

Susan D. Foster, Tufts  University - Antibiotic resistance issues in Uganda

Henrik Nielsen, UNICEF - Customization - Procurement process of tracer medicines

Nathalie Seigneuret, EMA - Regulatory incentives Experience from EMA

Lembit Rägo, WHO - Prequalification of Medicines Programme

Suzanne Hill, WHO - WHO-UNICEF, What do we need? The WHO/UNICEF wish list

Ahmet Afsar, UNICEF - Community case management experience

Angus Spiers, PSI -Angus Spiers - PSI - Social Marketing Approaches to Child Survival

 

For further information please contact Atieno Ojoo under aojoo@unicef.org


 

 

Latest

2011 List of priority medicines for maternal and child health, published by WHO: Read more.  


Essential Medicines for Children

Second WHO Model List of Essential Medicines for children,EMLc published in March 2009.

First Model Formulary for Children available since June 2010.

 

New enhanced search